Turnstone Biologics Restructures Workforce and Leadership to Focus on Cancer Therapy

Turnstone Biologics is implementing a significant workforce reduction, laying off about 60% of its employees as part of a strategic shift to concentrate resources on its TIDAL-01 tumor-infiltrating lymphocyte therapy. The company is redirecting its focus to this clinical-stage candidate, targeting colorectal, head and neck, and uveal melanoma, while deprioritizing other projects such as those in cutaneous melanoma and breast cancer[1][2]. The restructuring extends beyond workforce cuts, involving a reconfiguration of the C-suite roles to optimize the company's cash flow and extend its financial runway into the second quarter of 2026. These changes follow positive initial data from the TIDAL-01 trial and are designed to ensure continued progress in their cancer therapy trials[1][2].